SPEAKERS

Eunice Alvazzi is a dynamic and results-driven leader with extensive experience in market access and pricing.  She currently serving as Global Head of Complement, Access & Pricing focusing on Hematology, Nephrology, Transplant & Neurology therapeutic areas at Alexion – AstraZeneca Rare...

Ad Antonisse is a seasoned professional with over 15 years of experience in the pharmaceutical industry, currently serving as the Director of Market Access & Corporate Affairs at AstraZeneca. With a strong background in healthcare pricing, access, and evidence, Ad has a proven track record of...

Alex is Vice President of Commercial & Market Access at Memo Therapeutics, a private Swiss biotech company that focused on rare virological and oncological diseases.Prior, Alex was Vice President at AM-Pharma, a private dutch biotech company that focused on rare, kidney and critical care...

Dr. Antje Behring, PhD is a expert in evidence-based medicine, pharmaceutical benefit assessment, and health policy having worked in the Pharmaceuticals Department of the Federal Joint Committee (G-BA) in Germany for over a decade, first as a Scientific Advisor and then as Head of Department from...

Stefano Benvenuti is Head of Public Affairs and Market Access at Fondazione Telethon (Italy) since 2021. He is chair of the funders constituent committee of the International Rare Diseases Research Consortium (IRDiRC) and he is member of the Italian National Committee on Rare Disease. Within his...

Eric Bouteiller is adjunct professor of management at CEIBS (www.CEIBS.edu). He holds a PhD in organizational sociology and was a researcher at HEC Eurasia Institute before becoming deputy director (1990-2001). He then joined Ipsen Pharma where he held the position of China general manager and...

Vidya Breeveld is a market access and real-world evidence expert with nearly two decades of experience across the pharmaceutical industry, market access consultancy, and health data innovation. She has held senior roles in pricing, reimbursement, public affairs, and market access at leading...

Thomas Buijsman is an accomplished professional with extensive experience in the pharmaceutical industry, currently serving as the Associate Director of Medical Affairs in Oncology at Gilead Sciences. With a strong background in healthcare and a focus on oncology, Thomas is dedicated to improving...

Professor Dalia Dawoud, PhD, is the Director and CEO of PEHTA Consulting LTD. She has over 15-years’ experience as health economist, researcher and academic. Her work is largely focused on the application of health economics ad outcomes research (HEOR) in HTA and clinical guideline development. She ...

Eelko is Global Access, Strategy & Pricing Lead for Oncology Portfolio & Market Engagement. He joined Pfizer via the integration of Seagen where he served as the Head of International Market Access & Policy. Eelko has over 15 years industry experience in market access and policy...

Toon Digneffe is Head of Public Affairs & Public Policy Europe & Canada at Takeda. He has over 25 years’ experience in government affairs, communications, market access and patient advocacy at local, regional and global level.   Mr Digneffe has extensive experience in pharmaceutical...

Gina Ewy is a seasoned professional in the healthcare industry with more than 30 years experience in market access, pricing, value and policy. She is currently the Vice President and Head of Global Market Access at Hansa Biopharma. Her expertise lies in developing and implementing market access...

Dr. Flaherty is Director of Clinical Research at the Massachusetts General Hospital Cancer Center, and Professor of Medicine at Harvard Medical School.  As described in the more than 300 peer reviewed primary research reports he has authored or co-authored, Dr. Flaherty and colleagues made several...

DR. GÜNTER HARMS, Partner - ORPHAN NOW   

Amy Israel’s career spans diverse sectors and continents where she harnesses coalitions and evidence to improve health outcomes for those who need it most. She is currently Senior Advisor, Access to Medicines for the Union for International Cancer Control’s Access to Oncology Medicine...

Daniel Jackson is the Global Head of Payer Evidence Synthesis at UCB, where he leads the design and execution of payer evidence generation strategies that support sustainable patient access to innovative biopharmaceutical therapies across international markets. He directs global health economics...

Sven Klijn is Director at Bristol Myers Squibb in the Global HEOR Evidence Acceleration & Innovation group, where he leads the innovative modeling agenda in hematology and cell therapy. In addition, Sven has an active role in providing modeling and Generative AI education at international...

Dr Marisca Marian is a dynamic and results-driven professional with a proven track record in the pharmaceutical industry. Currently serving as the Global Access Strategy Lead for Oncology at Bayer, Marisca is at the forefront of shaping access strategies that ensure patients have timely and...

Lorenzo works as an independent advisor, collaborating with national governments, international organizations, NGOs, and companies to promote innovative regulatory pathways that enhance access to medicines and healthcare while advocating for anti-discrimination initiatives. Previously, he led the...

Helder Mota Filipe PhD in Pharmacology and graduate in Pharmaceutical Sciences.Associate Professor at the Faculty of Pharmacy of the University of Lisbon and member of its Scientific Council, President (Bastonário) of the Portuguese Pharmaceutical Society, Member of the National Council of Ethics...

Joep joined Gilde Healthcare in 2021. He focuses on investing in late-stage opportunities including publicly traded companies that deliver better care at lower cost. He is actively engaged in multi-stakeholder interaction and is responsible for coordinating Gilde’s Impact Council. Before joining...

Alexander Natz is the Secretary General of the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) in Brussels and advises innovative pharmaceutical and biotech companies, including start-ups, in regulatory and pricing & reimbursement matters from the EU law and German law...

Senior international Access & Policy leader, Anh has nearly two decades of experience in Value-Based Healthcare, for better patient access to innovations. She has led strategies that not only unlocked access & premium reimbursement, but also enabled policy change and sustainable adoption...

Sonia Pulido Sanchez holds a Bachelor of Science Degree in Pharmacy from Complutense University of Madrid, a Masters degree in Business Administration in the Pharmaceutical and Biotechnological Industry from Talento-EPHOS Business School and a Diploma in Health Technology Assessment from UNED...

Andras Ruppert is Vice President at Charles River Associates and has over 25 years of experience in the pharmaceutical industry, including 10 years in senior HEOR and P&MA roles within pharma companies before moving into consulting. At CRA, he specializes in payer value...

Ayman Semaan Market Access & Pricing Lead, Biologix Pharma Member, HTAi, Rare Diseases Working Group Ayman Semaan is the Market Access & Pricing Lead at Biologix Pharma, where he oversees strategy and execution across the Middle East and North Africa (MENA) region. With close to 20 years ...

Line Silsand is a senior researcher at the Norwegian Centre for E-Health Research, specializing in the assessment and implementation of digital health technologies (DHT). Her work explores how technology interacts with healthcare professionals and organizations during digital transformation, with a ...

Dr. Jeffrey L. Sturchio is visiting scholar at the Johns Hopkins University Institute for Applied Economics, Global Health, and the Study of Business Enterprise.    He is also chairman of Friends of the Global Fight Against AIDS, TB, and Malaria and chairman of the Internnational Society for Urban...

Siguroli Teitsson is a Director in Global HEOR Economic & Predictive Modeling at Bristol Myers Squibb. In his role, Siguroli leads the advancement of innovative modeling and analytics in oncology, and drives the integration of cutting-edge AI automations in HEOR and market access, streamlining...

Jörg Tomeczkowski is a seasoned professional with a wealth of experience in healthcare pricing, access, and evidence-based positioning. As the Director of HTA Strategy at the Institute for Evidence-Based Positioning in Healthcare, Jörg brings a unique blend of expertise in health technology...

Versatile senior leader with diverse public and private sector experience. Licensed health care professional (clinical pharmacist, licensed in Ontario, Canada). 30 years of pharmaceutical industry experience across GSK (Canada), Roche Canada (Vice President for 16 years leading Corporate...

Bart Van den Daele Director, Value & Access - Belgium & Luxembourg, Gilead Sciences With over 20 years in the biopharmaceutical industry, Bart specializes in creating patient access to life-saving treatments. At Gilead Sciences, Bart leads Market Access Strategies to ensure innovative...

Oliver van Zon has over 20 years of experience in the biopharmaceutical industry spanning market access, pricing, commercial strategy, and finance. Prior to joining Crinetics Pharmaceuticals as Vice President Market Access Europe where he is preparing their European endocrine launches, he held...

Yvette Venable Global Director Payer Partnerships and Policy Global Market Access & Pricing, Biopharma Business Unit, AstraZeneca   Ms. Venable is an accomplished life sciences leader, with more than 25 years’ experience in health policy, patient advocacy, and patient access. Currently, she ...

Marjan Willaert is Industrial Pharmacist who studied at the University of Antwerp (Belgium) and the University of Lille (France).She started her professional career in International & European Regulatory Affairs, first at Organon Teknika and later as a consultant. In the course of her...

Lara Wolfson, PhD, currently serves as the Associate Vice President and Head of HTA Statistics at MSD (known as Merck & Co. in the US and Canada), based in Brussels, Belgium.In this role, she oversees a dedicated team of over 75 statisticians, working collaboratively across the organization to...

Nicole Yurgin, PhD is a seasoned biopharma leader with 20+ years of experience across market access functions. She has held senior evidence and access roles at Lilly, Amgen, and Novartis, most recently as Global Head of Value and Access at Novartis, where she led teams in market...